1 results match your criteria: "Ospedale "Vito Fazzi" ASL (LE) - University of Salento[Affiliation]"
Is Going for Cure in CML Targeting Aberrant Glycogen Synthase Kinase 3β?
Curr Drug Targets
September 2017
Clinical Proteomics Laboratory, Polo Oncologico "Giovanni Paolo II", Ospedale "Vito Fazzi" ASL (LE) - University of Salento, Lecce, Italy.
Article Synopsis
- Chronic Myelogenous Leukemia (CML) initiating cells (CICs) have high levels of the BCR-ABL oncoprotein but do not replicate as quickly as other leukemic cells, and they maintain a stable primitive stem cell clone during disease progression.
- The dormant BCR-ABL+ CICs stay in a state of "proliferative quiescence," balancing their self-renewal and differentiation in response to cytokines.
- Targeting the protein GSK3β is being explored as a strategy to eliminate CML CICs while preserving normal blood cell production, with promising preclinical evidence for small-molecule inhibitors of GSK3β as potential anti-leukemia treatments.